Predictmedix AI Announces Closing of $460,150 First Tranche

Rhea-AI Summary

Predictmedix AI (OTC: PMEDF) announced the closing of the first tranche of a non-brokered private placement on November 17, 2025. The company issued 9,203,000 Units at C$0.05 per Unit, raising gross proceeds of $460,150. Each Unit includes one common share and one half warrant; each full Warrant allows purchase of one common share at C$0.15 and expires in 36 months. The warrant expiry may be accelerated if the 10-day VWAP reaches $0.30 after the four-month hold period. Insiders subscribed $60,000 of the tranche, and all securities are subject to a statutory hold of four months and one day.

Predictmedix said the financing follows recent European investor outreach, including participation at the 25th MK Investment Conference in Munich.

Positive

• Gross proceeds of $460,150 raised in the first tranche
• Issued 9,203,000 Units to expand liquidity and runway
• Insiders subscribed $60,000, signaling internal support

Negative

• Potential dilution from 9,203,000 Units issued
• Warrants exercisable at C$0.15 for 36 months, creating future dilution risk

News Market Reaction

+117.39%

1 alert

+117.39% News Effect

On the day this news was published, PMEDF gained 117.39%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company"), an emerging leader in AI-powered health and safety technology, is pleased to announce the successful closing of the first tranche of its non-brokered private placement. The Company issued 9,203,000 units ("Units") at an issue price of $0.05 per Unit, raising gross proceeds of $460,150. Notably, $60,000 of the tranche was subscribed by insiders, with Sheldon Kales and Dr. Rahul Kushwah each participating for $30,000, highlighting strong internal confidence in Predictmedix's future growth and innovation.

The Company issued 9,203,000 units ("Units") at a price of $0.05 per Unit, raising $460,150 in this tranche. Each Unit consists of one common share of Predictmedix and one half of one common share purchase warrant (each, a "Warrant"). Each Warrant will entitle the holder thereof to purchase one half Common Share of the Company at a price of C$0.15 for a period of 36 months following the closing date of the Offering. If, following four months and a day after the Closing Date, the volume weighted average price of the Common Shares on the CSE is equal to or greater than $0.30 for any 10 consecutive trading days, the Corporation may, upon providing written notice to the holders of Warrants, accelerate the expiry date of the Warrants to the date that is 30 days following the date of such written notice.

Insiders' participation in the Private Placement constitutes a "related party transaction" pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is relying on the exemption from the valuation and minority shareholder approval requirements under MI 61-101, as the fair market value of the Insiders' participation in the Private Placement does not exceed 25% of the market capitalization of the Company.

All securities issued in connection with the private placement are subject to a statutory hold period of four months and one day from the date of issuance.

Strategic Context & Investor Engagement

This financing round comes on the heels of Predictmedix's active engagement with European capital markets. Most recently, the Company participated in the 25th MK Investment Conference in Munich, Germany, a premier gathering of investors, family offices and private-market deal-makers focused on AI, longevity, tech and ESG themes. In parallel, earlier this year Predictmedix advanced its investor outreach via a high-profile European road-show, engaging influential family offices and institutional investors. These engagements reflect the Company's deliberate strategy to expand its shareholder base and build relationships among global investors aligned with its AI health-technology mission.

Details of the company's recent product validations, pilot programs, and strategic partnerships can be found in earlier press releases available at: https://predictmedix.com/press-releases/

About Predictmedix AI Inc.
Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Smarthealth AI stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedix AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at www.Predictmedix.com or follow us on Twitter, Instagram or LinkedIn.

Contact
Dr. Rahul Kushwah, COO
rahul@predictmedix.com
(647) 889 6916

Caution Regarding Forward-Looking Information:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

Disclaimer: The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274827

FAQ

What did Predictmedix (PMEDF) announce on November 17, 2025?

Predictmedix closed the first tranche of a private placement, issuing 9,203,000 Units at C$0.05 for gross proceeds of $460,150.

How many insiders participated in the Predictmedix (PMEDF) private placement and for how much?

Insiders subscribed $60,000 in the tranche, with Sheldon Kales and Dr. Rahul Kushwah each contributing $30,000.

What do the warrants in Predictmedix (PMEDF) Units allow and when do they expire?

Each Unit includes one half warrant (one full warrant per two Units) exercisable at C$0.15 for 36 months from closing, with possible acceleration if VWAP triggers.

When will securities from Predictmedix's (PMEDF) private placement be tradable?

All securities are subject to a statutory hold period of four months and one day from issuance.

Could Predictmedix (PMEDF) accelerate warrant expiry and under what condition?

Yes—if, after four months and one day, the 10-day VWAP on the CSE is ≥ $0.30, the company may accelerate warrant expiry to 30 days after notice.